<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-91e9c5c4=""><div class="content_outer_container" data-v-91e9c5c4=""><div class="share_preview_container" data-v-91e9c5c4=""><div class="dialog_list" data-v-91e9c5c4=""><div class="dialog_item" data-v-91e9c5c4=""><div class="dialog_question fir_dialog_question" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""><h1 class="fir_question_content" data-v-91e9c5c4="">
                                    How did NVCT's EPS perform in Q4 2024?
                                </h1> <div class="user_slot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-91e9c5c4=""> <span class="user_desction" data-v-91e9c5c4="">
                                        
                                        4/9/2025 02:13pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-91e9c5c4="">Nuvectis Pharma's EPS in Q4 2024 is not currently available. However, based on available data, the company's EPS for FY2024 is estimated to be ($1.00), with Q4 2024 earnings estimated at ($0.25). This indicates a potential decline in EPS performance in Q4 2024 compared to the previous quarter.</div> <div class="dialog_answer" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""> <div class="answer_robot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/AIme.ae832fb.png" alt="robot" class="avatar" data-v-91e9c5c4=""> <div class="user_name" data-v-91e9c5c4=""></div></div> <div class="question_content" data-v-91e9c5c4=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-4e97ba8a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-4e97ba8a=""> <div class="recommend-part" data-v-7790c618="" data-v-4e97ba8a=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:C,comeFrom:"AInvestShareLink",events:[],answerSource:q}],fetch:{},error:g,state:{sharePreviewModule:{loadJgySuccess:h,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:q,cache_builder:a,reply_action:"Answer",execute_mode:t,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did NVCT's EPS perform in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did NVCT's EPS perform in Q4 2024?\",\"user_id\":\"dp87412342\",\"user_name\":\"\",\"trace_id\":\"45efa6ce-4698-4635-9a82-73d637442bf8\",\"session_id\":\"45efa6ce-4698-4635-9a82-73d637442bf8\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:D,title:E,summary:F,full_summary:"Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital lifted their FY2024 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($1.00) for the year, up from their prior forecast of ($1.02). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at $1.64 EPS. Get Nuvectis Pharma alerts: Sign Up Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. During the same period in the prior year, the company earned ($0.37) EPS. Separately, HC Wainwright reaffirmed a \"buy\" rating and set a $21.00 target price on shares of Nuvectis Pharma in a research note on Tuesday, August 6th. View Our Latest Analysis on Nuvectis Pharma Nuvectis Pharma Trading Up 2.3 % NASDAQ NVCT traded up $0.19 during trading hours on Thursday, hitting $8.34. 303,425 shares of the company's stock were exchanged, compared to its average volume of 103,790. The stock has a 50-day simple moving average of $6.81 and a 200 day simple moving average of $6.68. Nuvectis Pharma has a 1-year low of $5.85 and a 1-year high of $12.10. The firm has a market cap of $155.54 million, a price-to-earnings ratio of -6.59 and a beta of 0.41. Ad True Gold Republic Central Bank Abandons USD Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Institution",url:G,image_url:a,video_url:a,publish_time:H,search_extra_info:{search_burial_info:{id:I,uid:u,ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]}}},simhash:"29d51474f27d9e8e",msg_id:u}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:C,trace_id:i,cost:11776,event_names:a,question:e,fallback_type:O,input_type:"typewrite",fall_back_reason:{fall_back_type:O,risk_detail:{matched_words:[]}},session_id:i,first_return_cost:2077,cache_type:a,question_id:i,transfer_question:e,signal_type:"ON_COMPLETE",start_time:P,remote_svc:q,slots:[],answer_type:t,user_id:v,skill_name:w},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:v,question:e,source:q,raw_question:e,version:"3.4.1",action_name:w,nlu:{entity:[{type:Q,value:"NVCT.O",market:R}]},deep_research:c,deep_thinking:c,agent_mode:N},extra:{}},{answer_path:j,section:{id:k,info_texts:["Thinking"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:j,section:{id:k,info_texts:["Querying Stock: NVCT EPS in Q4 2024"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:"Querying Stock",action_input:"NVCT EPS in Q4 2024",thought:"The user seeks to analyze NVCT's EPS performance in Q4 2024. I should focus on its EPS data for Q4 2024. I will use FinQuery for the data."}},{answer_path:d,section:{id:x,info_texts:[],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Searching Web: Nuvectis Pharma EPS in Q4 2024"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:"Searching Web",action_input:"Nuvectis Pharma EPS in Q4 2024",thought:"I am unable to obtain NVCT's EPS in Q4 2024 using FinQuery, now I will try again using Search."}},{answer_path:d,section:{id:x,info_texts:[],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:x,info_texts:[],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Generating Answer"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:y,info_texts:[],show_type:z,voice_txt:"N",text_answer:T,rich_text:T,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:z,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:G,image_url:a,video_url:a,title:E,summary:F,index:D,publish_time:H,search_id:I,search_uid:u,search_ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:y,info_texts:[],show_type:z,voice_txt:". This",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"NVCT",market_id:R,name:V,domain:Q},pos:h,section_id:y,txt:V,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Completed"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:m,query_text:m,trace_info:{item_id:"78b115fdd1399b32d6138046f4af2ad1",item_type:f,item_name:m,rec_info:W}},{display_text:n,query_text:n,trace_info:{item_id:"bb65d3ea1bc19bb7341ee07273f3ad8f",item_type:f,item_name:n,rec_info:X}},{display_text:o,query_text:o,trace_info:{item_id:"76310f07c2b78ef1bbfbf403305b6167",item_type:f,item_name:o,rec_info:Y}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:h,type:"1",display2:c,url:a}},request_config:[{source_type:Z,related_name:_}],puuid:A,tag:a,category:"custom",uuid:$}],global:{urp_static_data:[{name:_,value:{status_code:h,columns:[{type:p,index_name:aa,key:aa},{type:p,index_name:ab,key:ab},{type:p,index_name:ac,key:ac},{type:p,index_name:ad,key:ad},{type:p,index_name:ae,key:ae}],datas:[{send_text:m,item_type:f,rec_info:W,display_text:m,rec_reason:a},{send_text:n,item_type:f,rec_info:X,display_text:n,rec_reason:a},{send_text:o,item_type:f,rec_info:Y,display_text:o,rec_reason:a}],dataSize:Z,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:af,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:s,"min-height":"100%",position:ag,height:s},isMaterial:c,id:af,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:h,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:B,componentUuid:$,script:[{name:ah,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:B,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:B},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:s,position:ag,height:s},isMaterial:b,_id:19,id:ah,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ai,voice_txt:a,tracking_info:{},uuid:A},order:{is_auto:c,render_for:ai,chart_type:"command",puuid:A}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:r,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:w,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:t,answer_chain_name:M},is_deep_research:c,deep_thinking:c,create_time:1744179246023},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:g,docsData:[],quoteData:g},tplType:"question"},events:[],agentId:a}],userId:v,userName:a,startTime:P,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:g,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],traceTableData:g,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fnvcts-eps-perform-q4-2024-b0ac5a\u002F",config:{_app:{basePath:aj,assetsPath:aj,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","How did NVCT's EPS perform in Q4 2024?","llm_generated",null,0,"45efa6ce-4698-4635-9a82-73d637442bf8","progress\u002Fsearching_for",1000,"searching_for","⚖️ What are the current valuation ratios for NVCT?","⚙️ What were the key drivers of NVCT's Q4 2024 earnings?","📊 How did NVCT's Q4 2024 EPS compare to analyst expectations?","STR","ths_ainvest_lite_web","signal","auto","agent","219a1c3750cda51f","dp87412342","review stocks",999,2001,"rich_text","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Nuvectis Pharma's EPS in Q4 2024 is not currently available. However, based on available data, the company's EPS for FY2024 is estimated to be ($1.00), with Q4 2024 earnings estimated at ($0.25). This indicates a potential decline in EPS performance in Q4 2024 compared to the previous quarter.",2,"FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst","Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital lifted their FY2024 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per...","https:\u002F\u002Fwww.marketbeat.com\u002Finstant-alerts\u002Fnuvectis-pharma-fy2024-eps-estimate-boosted-by-roth-capital-2024-11-07\u002F","2024-11-06","219a1c3750cda51f_0","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE",1744179234247,"stock","186","thinking","Nuvectis Pharma's EPS in Q4 2024 is not currently available. However, based on available data, the company's EPS for FY2024 is estimated to be ($1.00), with Q4 2024 earnings estimated at ($0.25)[^2]",". This indicates a potential decline in EPS performance in Q4 2024 compared to the previous quarter.","Nuvectis Pharma","2+679_496_21_554+0+0+45efa6ce-4698-4635-9a82-73d637442bf8+78b115fdd1399b32d6138046f4af2ad1+llm_generated+aimeTagAnalysis+0+0.0797412171959877+1","2+679_496_21_554+0+0+45efa6ce-4698-4635-9a82-73d637442bf8+bb65d3ea1bc19bb7341ee07273f3ad8f+llm_generated+aimeTagAnalysis+0+0.06127273663878441+2","2+679_496_21_554+0+0+45efa6ce-4698-4635-9a82-73d637442bf8+76310f07c2b78ef1bbfbf403305b6167+llm_generated+aimeTagAnalysis+0+0.061157818883657455+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/195837b.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/e402278.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7c15041.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/69a864a.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/9579193.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/6726d3c.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/c69ce63.js" defer=""></script>